Generon Aiming High As It Progresses IL-22 Therapy
This article was originally published in PharmAsia News
Executive Summary
China’s Generon says it is the first company to develop an IL-22-targeting biologic for multiple therapeutic indications such as acute pancreatitis, acute alcoholic hepatitis and GvHD. With the project now entering Phase II trials in the US, the firm is seeking global licensing and collaboration opportunities and is open to fundraising from venture capital and strategic investors to support development.